Published online before print April 8, 2004, doi: 10.1161/01.RES.0000127719.13255.81
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Molecular Medicine |
Role of Fibroblast Growth Factor-2 Isoforms in the Effect of Estradiol on Endothelial Cell Migration and Proliferation
From INSERM U589 (B.G.-S., E.D., P.G., C.B., B.B., F.B., A.C.P., H.P., J.F.A.), Institut L. Bugnard, CHU Rangueil, Toulouse France; IGBMC (A.K.), Strasbourg, France; and the Department of Molecular Genetics (M.Z., T.D.), Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Correspondence to J.F. Arnal, INSERM U589, Institut L. Bugnard, CHU Rangueil, 31403 Toulouse, France. E-mail arnal{at}toulouse.inserm.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Both 17ß-estradiol (E2) and fibroblast growth factor-2 (FGF2) stimulate angiogenesis and endothelial cell migration and proliferation. The first goal of this study was to explore the potential link between this hormone and this growth factor. E2-stimulated angiogenesis in SC Matrigel plugs in Fgf2+/+ mice, but not in Fgf2–/– mice. Cell cultures from subcutaneous Matrigel plugs demonstrated that E2 increased both migration and proliferation in endothelial cells from Fgf2+/+ mice, but not from in Fgf2–/– mice. Several isoforms of fibroblast growth factor-2 (FGF2) are expressed: the low molecular weight 18-kDa protein (FGF2lmw) is secreted and activates tyrosine kinase receptors (FGFRs), whereas the high molecular weight (21 and 22 kDa) isoforms (FGF2hmw) remains intranuclear, but their role is mainly unknown. The second goal of this study was to explore the respective roles of FGF2 isoforms in the effects of E2. We thus generated mice deficient only in the FGF2lmw (Fgf2lmw–/–). E2 stimulated in vivo angiogenesis and in vitro migration in endothelial cells from Fgf2lmw–/– as it did in Fgf2+/+ mice. E2 increased FGF2hmw protein abundance in endothelial cell cultures from Fgf2+/+ and Fgf2lmw–/– mice. As shown using siRNA transfection, these effects were FGFR independent but involved FGF2-Interacting Factor, an intracellular FGF2hmw partner. This is the first report for a physiological role for the intracellular FGF2hmw found to mediate the effect of E2 on endothelial cell migration via an intracrine action.
Key Words: mouse • estradiol • growth factor • endothelium • migration
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Endothelium, being uniquely positioned at the interface between the blood and the vessel wall, plays a crucial role in the physiology of circulation by performing multiple functions.1,2 It is involved in the regulation of coagulation, leukocyte adhesion in inflammation, transvascular flux of cells, liquids, and solutes, vessel tone, and vascular smooth muscle growth. Endothelium also constitutes a target for the sex hormone, 17ß-estradiol (E2). Using a series of experimental models, E2 has been reported to promote angiogenic activity and endothelial cell migration and proliferation.3 The angiogenic effect is mediated through the estrogen receptor
(ER).4 However, the mechanisms involved downstream of ER remain unclear.5 Fibroblast growth factor-2 (FGF2) is an important mitogenic and angiogenic factor that stimulates endothelial cell growth and migration. Therefore, FGF2 could be a good candidate to be a partner of E2. However, FGF2 expression is complex because at least four (18, 22, 22.5, and 24 kDa) in human and three (18, 21, and 22 kDa) FGF2 isoforms in mouse are synthesized through the alternative use of translation initiation codons.6–9 These isoforms differ only in their NH2 extremities, which confer a nuclear localization to the high molecular weight CUG-initiated (22, 22.5, 24 or 21, and 22 kDa) isoforms (FGF2hmw), whose function is mainly unknown. In contrast, the smaller 18-kDa AUG-initiated FGF2 isoform (FGF2lmw) is predominantly cytoplasmic, excreted, and stored in the extracellular matrix.10 It stimulates cell proliferation and migration through binding to high-affinity transmembrane tyrosine kinase receptors (FGFR) and low-affinity receptors (heparan sulfate-containing proteoglycans), activating the mitogen-activated protein kinases (MAPKs) and/or phospholipase C-dependent pathways. Interestingly, E2 has been reported to stimulate MAPK activity via an autocrine loop involving FGF2.11 To achieve its proliferative activity, FGF2 needs to be internalized and translocated into the nucleus12 during the G1 phase of the cell cycle.13 In contrast, with the exception of human HSP 27-transfected endothelial cells,14 FGF2hmw remains intranuclear and interacts with several partners, such as FGF2 interacting factor (FIF)15 and survival of motor protein (SMN).16 These nuclear FGF2hmw promote cell proliferation independently of the cell surface receptors17 and are involved in tumor progression and metastatic dissemination.18
Levin and coworkers19 reported that transfection and expression of the 27-kDa human heat shock protein in bovine arterial endothelial cells double the rate of estrogen-induced FGF2 secretion, preferentially inducing the release of FGF2hmw. The secreted FGF2 is mitogenic to breast adenocarcinoma cells cultured in the conditioned medium obtained from the transfected endothelial cells. In contrast, decreasing the level of the endogenous heat shock protein homolog with an antisense vector markedly decreases FGF2 release.19 The same group reported later that although 18-kDa FGF2 promotes cell motility, FGF2hmw inhibited migration of endothelial cells by 50%, even in the presence of unrelated mitogens such as vascular endothelial growth factor (VEGF) and IGF-1 that promote cell migration.20 Using specific antibodies, they localized the inhibition of migration to the amino-terminal end and stimulation of growth to the 18-kDa domain of 24-kDa FGF2. They concluded that 24-kDa FGF2 affects cell behavior differently than 18-kDa FGF2.
The goal of the present work was to analyze the role of FGF2 in E2-induced angiogenesis, and possibly, the specific involvement of the molecular isoforms of this growth factor. In a first set of experiments, we explored the angiogenic effect of E2 in vivo in a mouse model of Matrigel plugs. The role of the FGF2 in the effect of E2 on the migration and proliferation of the microvascular endothelial cells provided by the Matrigel plugs grown in culture was then studied. Using knockout mice disrupted for the Fgf2 gene (Fgf2–/–),9 we demonstrated that endogenous FGF2 is absolutely required for the effects of E2. We also observed that E2 affected the abundance of FGF receptors and FGF2 isoforms.
Using mice specifically deficient in the 18-kDa FGF2lmw (Fgf2lmw–/–), we demonstrated that FGF2lmw was not required for the effects of E2. Indeed, this novel mouse model revealed that E2 effectively induced angiogenesis despite the absence of FGF2lmw. In addition, we found that E2 stimulated the migration, but not the proliferation, of microvascular endothelial cells from Fgf2lmw–/–. The role of the two partners of FGF2hmw, SMN and FIF, in the action of E2 were finally investigated.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Animal Studies
FGF2–/– mice were obtained as previously described.9 To produce the Fgf2lmw allele, the Hprt minigene in the tagged Fgf2– allele was "exchanged" by gene targeting with a mutant exon 1 with the sequence CTGCAG replacing the wild-type CCATGC (Figure 1A). The mutant sequence encodes an alanine GCA in place of the methionine ATG translational start site of the 18-kDa low molecular isoform of FGF2. The adjacent upstream wobble base was also changed from C to T so that the composite of these three base changes generated a PstI site that is diagnostic for the exchanged allele. Cells with the exchanged allele were selected for the loss of HPRT function using 5 µg/mL 6-thioguanine (Sigma), and the resulting ES cell line was injected into C57BL/6 blastocysts to generate germ-line chimeras. The germ-line chimeras were intercrossed with Black Swiss mice to generate Fgf2lmw+/– mice. The colony was maintained as an advanced intercross line on a mixed 129/SvEvxBlack Swiss background in order to avoid inadvertent recombinant inbreeding that can alter FGF2-deficient phenotypes.21
|
Fgf2lmw–/– mice were fertile and showed no obvious developmental defects. As expected, brain, aorta, and lung homogenates from Fgf2lmw–/– mice expressed exclusively FGF2hmw isoforms (Figure 1B). The background of Fgf2+/+, Fgf2–/–, and Fgf2lmw–/– mice was a mixed genetic background 129/SvEv x Black Swiss.9 ER–/– mice were previously described.22
All mice (Fgf2+/+, Fgf2–/–, Fgf2lmw–/–, ER–/–, and C57Bl/6) were ovariectomized at 4 weeks of age and implanted either with 60-day time-release E2 pellets (0.1 mg E2, Innovative Research of America, ie, releasing 80 µg/kg per day) SC into the back of the animals using a sterile trochar, or with placebo-releasing pellets.
At the time of euthanasia, serum was kept for hormone concentration measurement. Radioimmunoassay kits for E2 were used following manufacturer instructions (Sorin Biomedica, Italy).
Angiogenesis
On day 10 after ovariectomy and placebo or E2 treatment, the mice received a subcutaneous injection of Matrigel (0.5 mL) with 250 ng/mL FGF2.23 After 7 more days, the animals were killed, and the Matrigel plugs were cautiously removed from of the envelope wrapping them, to prevent fibroblast contamination, and incubated in 1.5 mL of Matrisperse cell release solution (BD Biosciences) during 2 hours at 4°C. After dispersion from the gel, cells were counted using Malassey cell. Their characterization as endothelial cells is indicated in the next section.
Endothelial Cell Cultures
Microvascular endothelial cells isolated as described were plated onto 5 µg/cm2 fibronectin-coated 35-mm dishes and cultured in Phenol-red-free Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 mmol/L L-glutamine and 10% charcoal-stripped fetal calf serum (CS-FCS) in a 10% CO2 atmosphere. All studies were performed on cells before any passage. Cultured cells were characterized using three markers of endothelial cells: rabbit polyclonal anti-CD31 (BD Pharmingen), rabbit polyclonal anti-vWF (DAKO, Via real, California), or isolectin Bandeiraea simplicifolia B4 conjugated to FITC (Sigma-Aldrich). The three techniques constantly showed that endothelial cells represented 
90% of the primary culture (data not shown).
When necessary, 5x10–8 mol/L of raloxifen (Eli Lilly), or 5x10–8 mol/L of ICI 182780 (Zeneca Pharmaceuticals) were incubated 30 minutes before E2 treatment. Untreated control culture received only ethanol (1:1000 final).
Cell Migration Assays
Cells were plated onto 35-mm dishes and cultured to 90% confluence in 2 mL phenol-red-free DMEM, 10% CS-FCS. Scratch injury was applied using a tip. The debris were removed by washing the cells with PBS, and the cells were incubated for 8 hours in phenol-red-free DMEM 2% CS-FCS supplemented with E2 (1 nmol/L) or FGF2 (3 ng/mL). The percentage of cell migration in vitro (ratio of the area that was recovered by migrating cells on area initially wounded, photographed with a Leica microscope) was determined using Leica Qwin standard V2.3 system. At least three experiments were performed.
Mitogenic assay, DNA synthesis analysis, reverse transcription, and real-time quantitative PCR are described in the expanded Materials and Methods section available in the online data supplement at http://circres.ahajournals.org.
RT-PCR, Enzyme Analysis, and Southern Blotting of FGFRs
RT were performed with a common oligonucleotide of FGFRs: 5'-GAGATGGAGATGATGAAA-3'. PCR were performed using another set of oligonucleotide for FGFR1: 5' primer 5'- AGTATGGGAGCATCAACC, 3' primer 5'-TGAGGTCATCACAGCTGG, and for FGFR2 as previously described.24 Fifty microliters of the PCR mixture was added along with the specific restriction enzymes for the following: FGFR1 IIIb, BstI; FGFR1 IIIc, AccI; FGFR2 IIIb, AvaI; and FGFR2 IIIc, EcoRV. Southern blotting were performed as previously described.24,25 The intensity of hybridization signals were quantified by densitometry using Phosphor Imager.
Transfection of Endothelial Cells With siRNA Duplexes
The 21-nucleotide siRNA duplexes were synthesized and purified by Dharmacon Research. The siRNA sequence targeting mouse Fif and Fgfr1 corresponded respectively to the coding region 951 to 972 and 1504 to 1525 relative to the first nucleotide at the start codon. The siRNA control was the scramble one from Dharmacon. The transfection was performed with 10 µmol/L of siRNA and oligofectamine reagent (Invitrogen) according to the manufacturer’s instructions.
Western Blotting
Proteins (30 µg) were boiled for 2 minutes in a Laemmli’s sample buffer solution and loaded onto 12.5% polyacrylamide gels containing SDS. They were transferred onto PVDF membrane and blocked in 3% nonfat milk TBST. Specific antibodies were used at a dilution of 1:1000. Polyclonal anti-FIF antibodies were generated as previously described.15 Mouse monoclonal anti-FGF2 (Ab3) was from Oncogene Science, and rabbit polyclonal against ERK2 (C14) mouse monoclonal against the phospho p44/p42 MAPK (E10) were purchased from Cell Signaling. Monoclonal anti–ß-actin (AC-15) was from Sigma Aldrich, and monoclonal anti-SMN was from BD Biosciences. HRP-labeled secondary antibodies were revealed by the ECL system.
Specific ELISA for FGF2
FGF2 in supernatants of endothelial cells were quantified using standard sandwich ELISA (Quantikine FGF basic, R&D Systems Inc) following the manufacturer’s instructions. The sensitivity of FGF2 assays was 10 pg/mL.
MAPK Activation
Endothelial cells were kept for 18 hours in serum-free medium. Cells were left untreated or stimulated with 3 ng/mL FGF2 during 10 minutes and then frozen before protein analysis. Proteins were separated on a 12.5% SDS-Polyacrylamide gel and subjected to immunoblotting with the indicated antibodies.
Statistics
Results are expressed as mean±SEM. To test the respective role of E2 treatment and of FGF2 genotypes, a two-factor ANOVA was performed (comparison of four groups). A value of P<0.05 was considered as statistically significant. When an interaction was observed between the two factors, the four groups were compared using a 1-factor ANOVA. The results of this test is also indicated by an asterisk when P<0.05 to facilitate the reading of the figures.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Characterization of the Mouse Models and Generation of the Fgf2lmw–/– Mice
Ovariectomized mice implanted with a placebo pellet showed undetectable (<5 pg/mL, ie, 20x10–12 mol/L) circulating levels of E2, whereas those implanted with a pellet releasing 0.1 mg E2 for 60 days (ie, 80 µg/kg per day) showed serum E2 concentrations 0.3 to 0.5 nmol/L, irrespective of the genotype (C57Bl/6, Fgf2+/+, Fgf2–/–, Fgf2lmw–/–, or ER
–/–). Similarly, ovariectomized placebo-treated mice showed an atrophied uterus (<20 mg), whereas E2-treated mice showed a significant increase in uterine weight irrespective of the genotype (not shown).
Role of ER and FGF2 in the Effect of E2 on In Vivo Angiogenesis
As previously described in an angiogenic model of exogenous FGF2-loaded Matrigel plugs,4 we found that E2 increased about 2-fold the number of endothelial cells in plugs from both C57Bl/6 and Fgf2+/+ mice, confirming the angiogenic effect of E2 in this model (Figure 2). The angiogenic effect of E2 was abolished in ER–/– mice,22 confirming in another model of ER gene inactivation22,26 that ER mediates the angiogenic effect of E2. The angiogenic effect of E2 was abolished in Fgf2–/– mice (P=0.41, NS). In contrast, the angiogenic effect of E2 in Fgf2lmw–/– was similar to that observed in Fgf2+/+ mice (Figure 2).
|
Role of ER and FGF2 in the Effect of E2 in Endothelial Cell Culture Experiments
E2 (1 nmol/L) significantly increased both the migration and cell proliferation of cultured endothelial cells obtained from the subcutaneous Matrigel plugs of Fgf2+/+ mice (Figures 3A and 3B). Raloxifen and ICI 182780 demonstrated a pure antagonist activity, and completely blocked the effect of E2 on endothelial cell proliferation and migration. Endothelial cells from ER–/– mice were completely unresponsive to E2, confirming again, that this ER isoform mediates the effect of E2 on both migration and proliferation (Figure 3).
|
Also, E2 did not increase significantly (P=0.16, NS) the migration (Figure 4A) and the 3H-thymidine incorporation (Figure 4B) of endothelial cells obtained from Fgf2–/– mice. In contrast, FGF2 (3 ng/mL) and VEGF (20 ng/mL) stimulated both the proliferation and the migration of cells from Fgf2–/– mice, although the effect of the former was attenuated on cell migration (53% compared with cells from Fgf2+/+ mice) (Figure 4A).
|
Interestingly, the effect of E2 on cell migration (Figure 4C), but not on 3H-thymidine incorporation (Figure 4D), was intact in cells obtained from Fgf2lmw–/– as well as the effect of exogenously added FGF2 and VEGF on both migration and 3H-thymidine incorporation in these cells.
Effect of E2 on FGF2 Isoforms, FGF Receptors, and FGF Signalization
The effect of E2 on FGF2 expression was then studied. As shown by Western blot analysis, untreated Fgf2+/+ endothelial cells expressed mainly the FGF2lmw isoform, whereas E2 treatment induced the FGF2hmw protein expression (Figure 5A). As previously reported,7 most of FGF2hmw was located in the nuclear fraction of Fgf2+/+ endothelial cells, and as expected, FGF2hmw was more abundant in nuclei from E2-treated endothelial cells than in untreated control (online Figure, available in the online data supplement). ELISA did not reveal the presence of FGF2 in the supernatant of either E2-treated or untreated cells (data not shown).
|
E2 treatment also increased the expression of FGF2hmw protein isoforms in cultured endothelial cell homogenates from FGF2lmw–/– mice to the same extent as in Fgf2+/+ cells (Figure 5B).
Unexpectedly, the abundance of Fgf2 mRNA was decreased by E2 treatment 2.5-fold in cultured endothelial cells (Figure 5C).
We then investigated the effect of E2 on FGF receptor expression. mRNA from endothelial cells were reverse-transcribed using a common oligonucleotide. The sequence coding the third immunoglobulin-like domain was amplified and restriction analysis was used to distinguish between the IIIb and IIIc variant of receptors (Figure 6A). We found that both FGFR1 and R2 are expressed in our primary cell cultures but essentially FGFR1 presented the splicing variant coding the FGF2 high affinity receptor isoform (FGFR1 IIIc) (Figure 6A). Using real-time PCR analysis, we showed that E2 increased FGFR1 IIIc mRNA 1.8-fold in Fgf2+/+ and 2-fold in Fgf2lmw–/– endothelial cells, whereas it has no effect on FGFR1 IIIc expression in Fgf2–/– endothelial cells (Figure 6B).
|
After determining the time course of FGF2-stimulated ERK phosphorylation in endothelial cells (Figure 7A), we found that FGF2-sustained ERK phosphorylation could be efficiently prevented by siRNA Fgfr1 transfection (Figure 7B), demonstrating the functional efficacy of FGFR blockade and the predominance of FGFR1 in the signal transduction of FGF2lmw. The Fgfr1 mRNA was significantly reduced after siRNA Fgfr1 transfection of endothelial cells (Figure 7C), but its blockade did not alter the E2-stimulated migration (Figure 7D), demonstrating the independence of E2-elicited migration from FGFR.
|
P<0.05 vs untreated cells.SMN was recently shown to specifically interact with FGF2hmw. SMN mRNA and protein were found to be expressed in cultured endothelial cells but no change of SMN expression could be detected after E2-treatment (Figure 8A and 8B). FIF was also recently found to be an intracellular partner of the HMW FGF2.15 The abundance of Fif mRNA and protein were then assessed in cultured endothelial cells, and both were found to be increased on E2 exposure (Figure 8C and 8D). The induction of FIF protein expression by E2 was also altered by siRNA, resulting in 80% inhibition, whereas scramble siRNA had no significant effect (Figure 8D). The partial suppression of Fif induced an attenuation of the stimulating effect of E2 on Fgf2+/+ cell migration and an abolition of the effect in Fgf2lmw–/– (Figure 8E), this result being in the line with the role of FGF2hmw.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
It is now clear that the effects of E2 are not limited to the field of reproduction but have many extrareproductive effects, in particular in the pathophysiology of atherosclerosis27 and in angiogenesis.3,28 Johns et al4 have shown that ER
mediates the stimulating effect of E2 on angiogenesis. In the present work, the angiogenic effect of E2 was abolished in ER–/– mice,22 a model of complete ER gene inactivation,26 confirming that the ER is required to mediate the angiogenic effect of E2, and the results of angiogenesis obtained in both transgenic models are valid. In addition, we found that the stimulating effect of E2 on endothelial cell migration and proliferation was mediated by ER and completely antagonized by raloxifene and ICI 182780.29
Because no growth factor downstream of the ER have been clearly identified to explain this effect, we investigated, in the present work, the role of FGF2, a potent angiogenic factor produced and secreted by endothelial cells, which promotes their migration, proliferation, chemotaxis, and protease production. Interestingly, in this model of Matrigel loaded with exogenous FGF2, basal angiogenesis was similar in Fgf2+/+ and in Fgf2–/– mice, endogenous FGF2 not being required. In contrast, endogenous FGF2 appears absolutely required for the E2-induced acceleration of this process. We thus showed for the first time, that the regenerative properties of E2 are dependent on endogenous FGF2.
We then explored the effect of E2 on FGF2 isoforms. FGF2 isoforms are synthesized through an alternative use of translation initiation codons.7–9 The smaller AUG-initiated FGF2 (FGF2lmw, 18 kDa) is predominantly cytoplasmic, excreted, and stored in the extracellular matrix.10 In the present work, we found that E2 increased FGF2hmw, but not FGF2lmw, abundance in cultured mouse endothelial cells, and we were unable to detect secreted FGF2 in the supernatant of these cells. This suggests that E2 specifically induces the expression of FGF2hmw. At the same time, Fgf2 mRNA concentration decreases. Such a discrepancy has been previously reported by us in 3T3 cells30 and others in erythroid cells.31 This strongly suggests a regulation at the translational level. Indeed, when the pool of silent mRNA is mobilized by the ribosomal machinery, its translation could activate its instability, possibly by removing masking-protein able to protect the instability region.31 Such a region has been clearly identified within the 3' end of Fgf2 mRNA.32 Furthermore, we have previously identified a translational enhancer located at the end of the 3' UTR of the Fgf2 gene, the activation of which promotes a preferential increase of the FGF2hmw forms.33 These two phenomena involving the role of the 3' UTR of Fgf2 mRNA could explain the effect observed here after stimulation by E2.
FGF2lmw is thought to stimulate proliferation and migration through tyrosine kinase receptors (FGFR), activating the MAPKs and/or phospholipase C-dependent pathways. The complex then translocates into the nucleus during the G1 phase of the cell cycle13 by a mechanism in which translokin appears to play a key role12 and is very distinct from the translocation of FGF2hmw, which is nuclearized by the importin machinery.8 Indeed, the nuclear localization sequence of the FGF2hmw is responsible of their nuclear localization, but their function is mainly unknown.
We thus explored the effect of E2 on the FGF receptors. We found that in mouse endothelial cells, FGFR1 IIIc and FGFR2 IIIb mRNA are expressed. E2 increased 1.8-fold FGFR1 IIIc mRNA in Fgf2+/+ endothelial cells, whereas it had no effect in Fgf2–/– endothelial cells. This suggests that an increase in FGFR1 signaling could have contributed to the effect of E2 on angiogenesis, migration, and proliferation. However, as shown in Figure 7, treatment of endothelial cells by siRNA against Fgfr1 reduces the level of its mRNA and fully inhibits both cell response as well as ERK phosphorylation in response to FGF2 stimulation, showing the dominant role of FGFR1 versus FGFR2 for MAPK activation. In these conditions, E2 is still active, demonstrating that the receptor-dependent pathways are not required to relieve the E2 effect.
The specific role of the FGF2 isoforms had previously been studied in various cell culture models but these studies provided conflicting data as recently pointed out by Boilly.34 Estrogen was reported to promote proliferation and migration via the activation of p42/44 and p38 MAPK in porcine aortic endothelial cells29; this activation was also reported to involve an autocrine loop by FGF2lmw in cultured human endothelial cells.11 In contrast, in a model of bovine aortic endothelial cells (BAECs) stably transfected with 27-kDa human HSP, but not in parental BAECs, FGF2hmw was found to inhibit migration under the influence of E2 by a mechanism involving activated MAPK and phosphorylated estrogen receptor.14,20 However, HSP27 protein expression was not altered by E2 in primary culture of mouse endothelial cells (B. Garmy-Susini, unpublished data, 2004). This goes along with the fact that FGF2hmw could not be detected in the supernatant of the cells.
Until the present work, very little was actually known about FGF2hmw mode of action. Thanks to the generation of mice deficient in FGF2lmw, we were able to demonstrate for the first time that FGF2hmw, is absolutely required for the stimulating effect of E2 on endothelial cell migration, whereas FGF2lmw appears dispensable for this effect (Figure 4C). However, both the intracrine FGF2hmw pathway and the classical auto/paracrine FGF2lmw pathway (including FGFR1 IIIc signaling) appear required to mediate the stimulating effect of E2 on 3H-thymidine incorporation (Figure 4D).
FGF2hmw has been shown to specifically interact with two mainly nuclear protein: FIF15 and SMN.16 SMN is essentially described as a key activator for snRNP assembly and recycling. The role of its association with FGF2hmw is still unclear. In our hands, we did not detect any modulation of the cellular content of SMN after E2 stimulation. Conversely, FIF expression was stimulated by E2 and its proposed role is in accordance with our results: FIF has been previously identified as an antiapoptotic factor,35 whose expression allows the synthesis of some matrix metalloproteases and the repression of TIMP-2. The functional role of FIF in cell migration was demonstrated in this study by the partial and complete abolition of the E2 effect by Fif siRNA duplex in cells from Fgf2+/+ and Fgf2lmw–/– mice, respectively.
The roles of FGF2 in many different systems, from brain and bone development, to arterial restenosis, vessel remodeling, differential functions of FGF2 and VEGF, fibrosis, wound healing, etc, coupled with the fact that there are FGF2 isoforms the functions of which are completely unknown but obviously important because they are conserved across species and their expression is differentially regulated across tissues, all make this gene and the function of its isoforms of considerable importance.
The present work demonstrates a novel link between FGF2 isoforms and estradiol in angiogenesis and endothelial cell migration and proliferation. Although the phenotype of Fgf2–/– mice suggest a dispensable role of E2-dependent angiogenesis in the domains of reproduction and development, the present data should be taken into consideration in pathophysiological circumstances such as atherosclerosis,36 collagen disease,37 diabetic angiogenesis,28 and possibly breast cancer,38 where both FGF2 and E2 have been suggested to be involved.
|
Acknowledgments |
|---|
The work was supported in part by INSERM, the Ministère de la Recherche et de la Technologie (ACI 2001 and 2003), the Fondation de France, the Fondation de l’Avenir, the Société Française d’HTA, the Conseil Régional Midi-Pyrénées (France), and NIH grant HL70174.
|
Footnotes |
|---|
*Both authors contributed equally to this study.
Original received January 9, 2004; revision received March 30, 2004; accepted March 31, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Alexander RW, Dzau VJ. Vascular biology: the past 50 years. Circulation. 2000; 102: IV-112–IV-116.[Medline] [Order article via Infotrieve]
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104: 365–372.
3. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995; 91: 755–763.
4. Johns A, Freay AD, Fraser W, Korach KS, Rubanyi GM. Disruption of estrogen receptor gene prevents 17ß estradiol-induced angiogenesis in transgenic mice. Endocrinology. 1996; 137: 4511–4513.[Abstract]
5. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999; 20: 358–417.
6. Florkiewicz RZ, Sommer A. Human FGF2 gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A. 1989; 86: 3978–3981.
7. Prats H, Kaghad M, Prats AC, Klagsbrun M, Lelias JM, Liauzun P, Chalon P, Tauber JP, Amalric F, Smith JA, Caput D. High molecular mass forms of FGF2 are initiated by alternative CUG codons. Proc Natl Acad Sci U S A. 1989; 86: 1836–1840.
8. Arnaud E, Touriol C, Boutonnet C, Gensac MC, Vagner S, Prats H, Prats AC. A new 34-kilodalton isoform of human FGF2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol. 1999; 19: 505–514.
9. Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, Yin M, Coffin JD, Kong L, Kranias EG, Luo W, Boivin GP, Duffy JJ, Pawlowski SA, Doetschman T. FGF2 control of vascular tone. Nat Med. 1998; 4: 201–207.[CrossRef][Medline] [Order article via Infotrieve]
10. Florkiewicz RZ, Anchin J, Baird A. The inhibition of FGF2 export by cardenolides implies a novel function for the catalytic subunit of Na+,K+-ATPase. J Biol Chem. 1998; 273: 544–551.
11. Kim-Schulze S, Lowe WL Jr, Schnaper HW. Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves FGF2. Circulation. 1998; 98: 413–421.
12. Bossard C, Laurell H, Van den Berghe L, Meunier S, Zanibellato C, Prats H. Translokin, a novel intracellular mediator of FGF-2 trafficking. Nat Cell Biol. 2003; 5: 433–439.[CrossRef][Medline] [Order article via Infotrieve]
13. Baldin V, Roman AM, Bosc-Bierne I, Amalric F, Bouche G. Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. EMBO J. 1990; 9: 1511–1517.[Medline] [Order article via Infotrieve]
14. Piotrowicz RS, Maher PA, Levin EG. Dual activities of 22–24 kDa basic fibroblast growth factor: inhibition of migration and stimulation of proliferation. J Cell Physiol. 1999; 178: 144–153.[CrossRef][Medline] [Order article via Infotrieve]
15. Van den Berghe L, Laurell H, Huez I, Zanibellato C, Prats H, Bugler B. FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2. Mol Endocrinol. 2000; 14: 1709–1724.
16. Claus P, Doring F, Gringel S, Muller-Ostermeyer F, Fuhlrott J, Kraft T, Grothe C. Differential intranuclear localization of FGF2 isoforms and specific interaction with the survival of motoneuron protein. J Biol Chem. 2003; 278: 479–485.
17. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB. Differential modulation of cell phenotype by different molecular weight forms of FGF2: possible intracellular signaling by the high molecular weight forms. J Cell Biol. 1995; 129: 233–243.
18. Okada-Ban M, Moens G, Thiery JP, Jouanneau J. Nuclear 24 kD FGF-2 confers metastatic properties on rat bladder carcinoma cells. Oncogene. 1999; 18: 6719–24.[CrossRef][Medline] [Order article via Infotrieve]
19. Piotrowicz RS, Martin JL, Dillman WH, Levin EG. The 27-kDa heat shock protein facilitates FGF2 release from endothelial cells. J Biol Chem. 1997; 272: 7042–7047.
20. Piotrowicz RS, Ding L, Maher P, Levin EG. Inhibition of cell migration by 24-kDa fibroblast growth factor-2 is dependent upon the estrogen receptor. J Biol Chem. 2001; 276: 3963–3970.
21. Doetschman T. Interpretation of phenotype in genetically engineered mice. Lab Anim Sci. 1999; 49: 137–143.[Medline] [Order article via Infotrieve]
22. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ER) and beta (ERß) on mouse reproductive phenotypes. Development. 2000; 127: 4277–4291.[Abstract]
23. Patry V, Arnaud E, Amalric F, Prats H. Involvement of basic fibroblast growth factor NH2 terminus in nuclear accumulation. Growth Factors. 1994; 11: 163–174.[Medline] [Order article via Infotrieve]
24. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Harkonen PL. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 2001; 61: 4229–4237.
25. Jones RB, Wang F, Luo Y, Yu C, Jin C, Suzuki T, Kan M, McKeehan WL. The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs. J Biol Chem. 2001; 276: 4158–4167.
26. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS, Bayard F, Arnal JF. The AF-1 activation-function of ER may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A. 2002; 99: 2205–2210.
27. Hodgin J, Maeda N. Estrogen and mouse models of atherosclerosis. Endocrinology. 2002; 143: 4495–4501.
28. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001; 21: 6–12.
29. Geraldes P, Sirois MG, Bernatchez PN, Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2002; 22: 1585–1590.
30. Galy B, Creancier L, Zanibellato C, Prats AC, Prats H. Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism. Oncogene. 2001; 20: 1669–1677.[CrossRef][Medline] [Order article via Infotrieve]
31. Weiss IM, Liebhaber SA. Erythroid cell-specific mRNA stability elements in the alpha 2-globin 3' nontranslated region. Mol Cell Biol. 1995; 15: 2457–2465.
32. Touriol C, Morillon A, Gensac MC, Prats H, Prats AC. Expression of human fibroblast growth factor 2 mRNA is post-transcriptionally controlled by a unique destabilizing element present in the 3'-untranslated region between alternative polyadenylation sites. J Biol Chem. 1999; 274: 21402–21408.
33. Touriol C, Roussigne M, Gensac MC, Prats H, Prats AC. Alternative translation initiation of human fibroblast growth factor 2 mRNA controlled by its 3'-untranslated region involves a Poly(A) switch and a translational enhancer. J Biol Chem. 2000; 275: 19361–19367.
34. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V, Le Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 2000; 11: 295–302.[CrossRef][Medline] [Order article via Infotrieve]
35. Kim JW, Cho HS, Kim JH, Hur SY, Kim TE, Lee JM, Kim IK, Namkoong SE. AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis. Lab Invest. 2000; 80: 587–594.[Medline] [Order article via Infotrieve]
36. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–125.
37. Kadono T, Kikuchi K, Kubo M, Fujimoto M, Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol. 1996; 35: 392–397.[CrossRef][Medline] [Order article via Infotrieve]
38. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 1999; 10: 707–713.
This article has been cited by other articles:
 |
|
 |
|
  L. Xiao, P. Liu, X. Li, T. Doetschman, J. D. Coffin, H. Drissi, and M. M. Hurley Exported 18-kDa Isoform of Fibroblast Growth Factor-2 Is a Critical Determinant of Bone Mass in Mice J. Biol. Chem., January 30, 2009; 284(5): 3170 - 3182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Toutain, L. Brouchet, I. Raymond-Letron, P. Vicendo, H. Berges, J. Favre, M.-J. Fouque, A. Krust, A.-M. Schmitt, P. Chambon, et al. Prevention of Skin Flap Necrosis by Estradiol Involves Reperfusion of a Protected Vascular Network Circ. Res., January 30, 2009; 104(2): 245 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Gorjestani, V Rider, B. Kimler, C Greenwell, and N. Abdou Extracellular signal-regulated kinase 1/2 signalling in SLE T cells is influenced by oestrogen and disease activity Lupus, June 1, 2008; 17(6): 548 - 554. [Abstract] [PDF]
|
|
|
|
 |
|
 R. O'Lone, K. Knorr, I. Z. Jaffe, M. E. Schaffer, P. G. V. Martini, R. H. Karas, J. Bienkowska, M. E. Mendelsohn, and U. Hansen Estrogen Receptors {alpha} and {beta} Mediate Distinct Pathways of Vascular Gene Expression, Including Genes Involved in Mitochondrial Electron Transport and Generation of Reactive Oxygen Species Mol. Endocrinol., June 1, 2007; 21(6): 1281 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fontaine, C. Filipe, N. Werner, P. Gourdy, A. Billon, B. Garmy-Susini, L. Brouchet, F. Bayard, H. Prats, T. Doetschman, et al. Essential Role of Bone Marrow Fibroblast Growth Factor-2 in the Effect of Estradiol on Reendothelialization and Endothelial Progenitor Cell Mobilization Am. J. Pathol., November 1, 2006; 169(5): 1855 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pedram, M. Razandi, and E. R. Levin Nature of Functional Estrogen Receptors at the Plasma Membrane Mol. Endocrinol., September 1, 2006; 20(9): 1996 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Cao, N. Dronadula, F. Rizvi, Q. Li, K. Srivastava, W. T. Gerthoffer, and G. N. Rao Novel Role for STAT-5B in the Regulation of Hsp27-FGF-2 Axis Facilitating Thrombin-Induced Vascular Smooth Muscle Cell Growth and Motility Circ. Res., April 14, 2006; 98(7): 913 - 922. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||